{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:31:21Z","timestamp":1777573881043,"version":"3.51.4"},"reference-count":23,"publisher":"ALUNA","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:p>Aim: To explore link between circulating Growth Differentiation Factor 11 (GDF11) levels and atherogenic lipid parameters in individuals with diabetic dyslipidemia, and to evaluate whether GDF11 may serve as a potential biomarker to minimize atherosclerosis in this population.\nMaterials and methods: A cross-sectional study was conducted at AL-Hassn Metabolism, Endocrine, and Diabetes Center in Kerbala, Iraq, February-April, 2025. A 172 participants with either type 1 or type 2 diabetes mellitus. Diabetic patients with dyslipidemia (n=90, 52 male and 38 female), with 4 having type 1 diabetes, 86 having type 2 diabetes, and without dyslipidemia (n=86: 36 male and 46 female), with 28 having type 1 diabetes and 54 having type 2 diabetes. Ages 20-70 years, serum level of GDF11 was determined using ELISA method. Atherogenic marker measures include midkine, NLRP3 inflammasome, PPARy and oxidative stress. Additional data obtained included age, BMI, duration of diabetes, fasting glucose, and liver enzyme (ALT). Link between GDF11 and atherogenic markers was assessed using Spearman\u2019s correlation analysis to assess independent connections, multivariate regression analysis was performed, with adjustments for age, BMI, and glycemic control.\nResults: diabetic individuals with dyslipidemia had considerably greater levels of all biomarkers tested (GDF11, SOD, NLRP3, MIDKINE, and PPARy) than with diabetes alone. Diabetes and dyslipidemia are linked to increased oxidative stress (SOD), heightened inflammation (NLRP3, Midkine), and altered metabolic regulation (GDF11, ppary).\nConclusions: Diabetes with dyslipidemia linked to elevated levels of GDF11, SOD, NLRP3, midkine and PPARy, indicating increased oxidative stress, inflammation, and metabolic dysregulation.<\/jats:p>","DOI":"10.36740\/merkur202602107","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:20:38Z","timestamp":1777404038000},"page":"144","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of correlation of GDF11 and atherogenic factors in patients with diabetic dyslipidemia"],"prefix":"10.36740","volume":"54","author":[{"given":"Nagham Yahya","family":"Ghafil","sequence":"first","affiliation":[{"name":"DEPARTMENT PHYSIOLOGY, FACULTY OF PHARMACY, UNIVERSITY OF KUFA, NAJAF, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sura Hadi Ibraheim","family":"Abd Ali","sequence":"additional","affiliation":[{"name":"KARBALA HEALTH DEPARTMENT, PHARMACIST AT THE CENTRAL SECTOR, KARBALA, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diab Endocrinol. 2021; 9(3):174-188. doi: 10.1016\/S2213-8587(20)30381-8.","DOI":"10.1016\/S2213-8587(20)30381-8"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Anusha G, Sunayana R, Ponnam M, Kumar BA. Phytochemical Investigation and In Vitro Antidiabetic Activity of Melothria Scabra. Asian J Pharm Res Dev. 2019;7(4):43-48. doi: 10.22270\/ajprd.v7i4.553.","DOI":"10.22270\/ajprd.v7i4.553"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and Treatment of Dyslipidemia in Diabetes. Curr Cardiol Rep. 2021;23(4). doi: 10.1007\/s11886-021-01455-w.","DOI":"10.1007\/s11886-021-01455-w"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Gusev E, Sarapultsev A. Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. Int J Mol Sci. 2023 Apr 26;24(9):7910. doi: 10.3390\/ijms24097910.","DOI":"10.3390\/ijms24097910"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Majaj M, Weckbach LT. Midkine -A novel player in cardiovascular diseases. Front. Cardiovasc. Med. 2022;9:1-59. doi: 10.3389\/fcvm.2022.1003104.","DOI":"10.3389\/fcvm.2022.1003104"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Khair M, Vangaveti VN, Malabu UH. The role of the NLRP3 inflammasome in atherosclerotic disease: Systematic review and meta-analysis. J Cardiol. 2024; 84(1): 14-21. doi: 10.1016\/j.jjcc.2024.03.003.","DOI":"10.1016\/j.jjcc.2024.03.003"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Staels B. PPAR\u03b3 and atherosclerosis. Curr Med Res Opin. 2005;21(1):15811195. doi: 10.1185\/030079905X36440.","DOI":"10.1185\/030079905X36440"},{"key":"ref7","unstructured":"8. Kalra A, Yetiskul E, Wehrle CJ, Tuma F. Physiology, Liver. Treasure Island (FL): StatPearls Publishing; 2025, pp. 1-9."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Simoni-Nieves A, Gerardo-Ramirez M, Pedraza-Vazquez G, Chavez-Rodriguez L et al., GDF11 Implications in Cancer Biology and Metabolism. Facts and Controversies. Front Oncol. 2019 Oct 15;9:1039. doi: 10.3389\/fonc.2019.01039.","DOI":"10.3389\/fonc.2019.01039"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Walker RG, Kato T, Ben Driss LB, Williams SA, et al. Activated GDF11\/8 subforms predict cardiovascular events and mortality in humans. Nat Commun. 2025;16(1). doi: 10.1038\/s41467-025-61815-w.","DOI":"10.1038\/s41467-025-61815-w"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Cho SMJ, Lee HJ, Shim JS, Song BM, Kim HC. Associations between age and dyslipidemia are differed by education level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. Lipids Health Dis. 2020;19(1):1-31. doi: 10.1186\/s12944-020-1189-y.","DOI":"10.1186\/s12944-020-1189-y"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Hussain A, Ali I, Kaleem WA, Yasmeen F. Correlation between body mass index and lipid profile in patients with type 2 diabetes attending a tertiary care hospital in Peshawar. Pakistan J Med Sci. 2019; 35(3): 591-597. doi: 10.12669\/pjms.35.3.7.","DOI":"10.12669\/pjms.35.3.7"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Zheng C, Liu Y, Xu C, Zeng S, et al. Association between obesity and the prevalence of dyslipidemia in middle-aged and older people: an observational study. Sci Rep. 2024;14(1):1-26. doi: 10.1038\/s41598-024-62892-5.","DOI":"10.1038\/s41598-024-62892-5"},{"key":"ref13","unstructured":"14. Gilani SYH, Bibi S, Ahmed N, Shah SRA. Gender differences of dyslipidemia in type 2 diabetics. J Ayub Med Coll Abbottabad. 2010;22(3):146-148."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Haley JE, Urbina EM. Insulin Resistance and Cardiovascular Disease. Contemp. Endocrinol. 2020; 195-205. doi: 10.1007\/978-3-030-25057-7_12.","DOI":"10.1007\/978-3-030-25057-7_12"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Taskinen MR. Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia. 2003;46(6):733-749. doi: 10.1007\/s00125-003-1111-y.","DOI":"10.1007\/s00125-003-1111-y"},{"key":"ref16","unstructured":"17. Al-Jameil N, Khan FA, Arjumand S, Khan MF, Tabassum H. Associated liver enzymes with hyperlipidemic profile in type 2 diabetes patients. Int. J. Clin. Exp. Pathol. 2014; 7(7): 4345-4349."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Shao Y, Liu T, Wen X, Zhang R, Liu X, Xing D, The regulatory effect of growth differentiation factor 11 on different cells,\u201d Front. Immunol. 2023;14:1-33. doi: 10.3389\/fimmu.2023.1323670.","DOI":"10.3389\/fimmu.2023.1323670"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Salman IN, Mohammed NGU, Shaban A, Abed BA, Mutar SA, Omran HH. Clinical relevance of midkine as a biomarker predicting atherosclerotic risk factors in individuals with type-2 diabetes mellitus: a cross-sectional study. J. Diabetes Metab. Disord. 2025;24(1):5-6. doi: 10.1007\/s40200-024-01547-8.","DOI":"10.1007\/s40200-024-01547-8"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Bai Y, Mu Q, Bao X, Zuo J, et al. Targeting NLRP3 inflammasome in the treatment of diabetes and diabetic complications: Role of natural compounds from herbal medicine. Aging Dis. 2021;12(7):1587-1604. doi: 10.14336\/AD.2021.0318.","DOI":"10.14336\/AD.2021.0318"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Ahmadian M, Suh JM, Hah N, Liddle C, et al. Ppar\u03b3 signaling and metabolism: The good, the bad and the future. Nat Med. 2013 May 7; 19(5):10.1038\/nm.3159. doi: 10.1038\/nm.3159.","DOI":"10.1038\/nm.3159"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Choi SS, Park J, Choi JH. Revisiting PPAR\u03b3 as a target for the treatment of metabolic disorders. BMB Rep. 2014 Nov;47(11):599-608. doi: 10.5483\/ BMBRep.2014.47.11.174.","DOI":"10.5483\/BMBRep.2014.47.11.174"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Tavares AM, Silva JH, de Oliveira Bensusan C, Ferreira ACF, et al. Altered superoxide dismutase-1 activity and intercellular adhesion molecule 1 (ICAM-1) levels in patients with type 2 diabetes mellitus. PLoS One. 2019; 14(5):1-7. doi: 10.1371\/journal.pone.0216256.","DOI":"10.1371\/journal.pone.0216256"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:20:50Z","timestamp":1777404050000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek20026i2net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202602107","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}